Galectin Therapeutics Inc. (GALT)

3,4700 +0,1300 (+3,89%) Al cierre: 04:00PM EDT

Galectin Therapeutics Inc.

4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
(678) 620-3186
https://galectintherapeutics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 28

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Joel Lewis	President, CEO & Director	907,72k	N/A	1970
Mr. Jack W. Callicutt CPA	CFO, Treasurer & Corporate Secretary	521,47k	N/A	1967
Dr. Pol F. Boudes M.D., Ph.D.	Chief Medical Officer	730,33k	N/A	1957
Robert Tritt	General Counsel	N/A	N/A	N/A
Mr. Jeff Katstra	Head of CMC & Pharmaceutical Development	N/A	N/A	N/A
Ms. Beth Knowles	Executive Assistant & Officer Manager	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Gobierno corporativo

El ISS Governance QualityScore de Galectin Therapeutics Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.